The hemophilia A treatment could become the company’s second gene therapy to enter the U.S. market after Beqvez, which was cleared in April for hemophilia B.
More Stories
Disney to ditch Slack following July data breach
The company's Slack server was hacked in July, leading to more than a terabyte of company data being leaked to...
Nike CEO John Donahoe is out, replaced by company veteran Elliott Hill
Nike CEO John Donahoe will retire from the company in October. He will be replaced by company veteran Elliott Hill.
WIF, PEPE, and SEI shine as cryptocurrencies surge
WIF, PEPE and SEI were among top performing altcoins as Bitcoin surged to above $63,800 on Sept. 19. These gains...
Civil rights groups call on Fortune 1000 companies to stop ‘abandoning DEI’
Nearly two dozen civil rights organizations are calling on America's largest companies to stand up against anti-DEI campaigns.
Pixelverse debuts TON Microtransactions outside Telegram with beta browser game launch
Pixelverse launches a closed beta MMORPG browser game with TON microtransactions. The game marks the first TON integration outside Telegram,...
Tether invests $1.5 million in Sorted Wallet
Tether announced its $1.5 million strategic investment in Sorted Wallet on Sept. 19. Sorted Wallet will tap into this investment...